Parnax Lab Limited reported a consolidated net profit of ₹1,177.68 lakh for the financial year ended March 31, 2026, an increase from ₹1,151.90 lakh in the previous year. Total revenue for the year rose to ₹25,232.56 lakh, compared to ₹18,941.44 lakh in FY25. The company's board approved the audited standalone and consolidated financial results for the quarter and year ended March 31, 2026, at a meeting held on May 28, 2026.

Consolidated Financial Performance

For the quarter ended March 31, 2026, the company reported a profit after tax of ₹217.65 lakh on a total revenue of ₹7,161.93 lakh. In the corresponding quarter of the previous year, the profit after tax was ₹291.98 lakh on revenue of ₹4,946.43 lakh. Total expenses for the quarter stood at ₹6,839.23 lakh. The company recognized exceptional items amounting to ₹23.13 lakh during the quarter, primarily due to the impact of new Labour Codes regarding gratuity and compensated absences.

For the full year, profit before exceptional items and tax was ₹1,727.63 lakh, up from ₹1,567.42 lakh in the prior year. Exceptional items for the year totaled ₹136.93 lakh. Earnings per share (EPS) for the year were reported at ₹10.27 on a non-annualised basis.

Standalone Results

On a standalone basis, the company reported a total revenue of ₹236.55 lakh for the year ended March 31, 2026, compared to ₹70.95 lakh in the previous year. The standalone financial results reflected a loss before tax of ₹3.49 lakh for the year, primarily due to exceptional items of ₹68.19 lakh related to Labour Code compliance. For the quarter ended March 31, 2026, standalone revenue was ₹176.22 lakh, with a loss before tax of ₹1.33 lakh.

Board Decisions and Governance

The Board of Directors approved the re-appointment of Mr. Yogesh K. Varia as a Non-Executive Independent Director for a second term of five consecutive years, effective from May 28, 2026, to May 27, 2031. The appointment is subject to shareholder approval at the ensuing general meeting. Mr. Varia is not related to any of the directors or key managerial personnel of the company.

The statutory auditors, M/s. C. N. Patel & Co., issued an unmodified opinion on the standalone and consolidated financial results. The financial statements were prepared in compliance with Indian Accounting Standards (Ind AS) and the regulations of the Securities and Exchange Board of India (SEBI).

Financial Position

The consolidated assets of the company as of March 31, 2026, stood at ₹22,762.97 lakh, an increase from ₹18,981.84 lakh in the previous year. Total equity and liabilities were reported at ₹22,762.97 lakh. Cash and cash equivalents decreased to ₹33.64 lakh from ₹54.99 lakh at the end of the previous year.

Parnax Lab Limited has announced that its board of directors will meet on Thursday, May 28, 2026, at the company's registered office. The primary agenda of the meeting is to consider and approve the standalone and consolidated audited IND-AS compliant financial results for the quarter and year ended March 31, 2026. The approval is pursuant to Regulation 33 of the Listing Obligation and Disclosure Requirements, 2015.

Agenda for the Meeting

The board will deliberate on the financial performance for the fourth quarter and the full fiscal year. The approved results, along with the auditor's report, will be submitted to the stock exchanges following the conclusion of the board meeting.

Trading Window Closure

In compliance with the Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015, the company has closed the trading window for dealing in its equity shares. The closure is effective from April 1, 2026, for designated persons. The window will remain closed until 48 hours after the declaration of the audited financial results.